138 results
CORRESP
ATOS
Atossa Therapeutics Inc
3 Oct 12
Correspondence with SEC
12:00am
be considered in this determination, including:
Whether the nature of the revenue-producing activity will generally remain the same after the asset … be considered, it is important to assess the nature of the revenue-producing activity and whether this activity will generally remain the same after the asset
CORRESP
ATOS
Atossa Therapeutics Inc
18 Jun 12
Correspondence with SEC
12:00am
expanded our disclosures to more clearly identify the risks to investors of the “no-minimum” nature of the offering on pages 5 and 19. In light of guidance … in the prior period, please tell us the nature of these direct costs.
The Company acknowledges the Staff’s comment and advises the Staff
8-K
EX-4.2
qiy uk50ty
15 Jan 19
Departure of Directors or Certain Officers
4:10pm
D/A
mx2g2 npmthy8blw3
28 Sep 10
$173K in equity, sold $173K, 48 investors
12:00am
D
1fc5 iwjyq2glos
24 Jun 10
$106K in equity, sold $106K, 48 investors
12:00am
D
qc2j031g nmw
11 Apr 13
$30M in equity, sold $1M, 1 investor
12:00am
S-8
EX-99.1
e1ya8h bn39
31 Mar 21
Registration of securities for employees
2:30pm
D/A
6zg9545t745ptmq
24 Jun 11
$6.57M in equity / options / securities to be acquired, sold $6.57M, 156 investors
12:00am